Fan Wang1, Ping Ye2, Dayi Hu3, Ying Min1, Shuiping Zhao4, Yongjun Wang5, Yiming Mu6, Xiaowei Yan7, Zhanquan Li8, Yidong Wei9, Jihu Li10. 1. Department of Geriatric Cardiology, Chinese PLA General Hospital, No.28, Fuxing Rd, Haidian District, Beijing 100853, China. 2. Department of Geriatric Cardiology, Chinese PLA General Hospital, No.28, Fuxing Rd, Haidian District, Beijing 100853, China. Electronic address: yeping301@sina.com. 3. Department of Cardiology, Peking University People's Hospital, No.11, Xi Zhi Men Nan Da Jie, Xicheng District, Beijing 100044, China. 4. Department of Cardiology, Second Xiangya Hospital, Central South University, No.139, People Street (M.), Changsha 410011, China. 5. Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, No. 6, Tiantan Xi Li, Dongcheng District, Beijing 100050, China. 6. Department of Endocrinology, Chinese PLA General Hospital, No.28, Fuxing Rd, Haidian District, Beijing 100853, China. 7. Department of Cardiology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, No.1, Shuai Fu Yuan, Dongcheng District, Beijing 100730, China. 8. Department of Cardiology, The People's Hospital of Liaoning Province, No. 33, Wen Yi Rd., Shenhe District, Shenyang 110016, China. 9. Department of Cardiology, Tenth People's Hospital of Tongji University, No. 301, Yanchang Rd. (M), Shanghai 200072, China. 10. MSD China Holding Co., Ltd., No. 1601, Nanjing Rd.(W), JingAn District, Shanghai 20004, China.
Abstract
OBJECTIVE: To objectively evaluate lipid-lowering therapy and low-density lipoprotein cholesterol (LDL-C) and non-high-density lipoprotein cholesterol (non-HDL-C) goal attainment in metabolic syndrome (MetS) patients in China. METHODS: Data regarding patient demographics, lipid-lowering agents, lipid parameters, and cardiovascular risk profiles were analyzed for 25,317 patients of the Dyslipidemia International Study-China. MetS was defined according to criteria of the NCEP-ATP III and the 2007 Chinese Guidelines on Prevention and Treatment of Dyslipidemia in Adults. RESULTS: The prevalence of MetS was 39.9% and 37.4% according to the NCEP-ATP III and 2007 Chinese Guidelines, respectively. LDL-C goal attainment occurred less frequently among MetS patients than in those without MetS (NCEP-ATP III: 46.9% vs 68.6%; 2007 Chinese Guidelines: 52.2% vs 67.1%; p < 0.001). Similar results were obtained for non-HDL-C goal attainment (2007 Chinese Guidelines: 51.0% vs 72.0%; p < 0.001). As the risk class increased, LDL-C and non-HDL-C goal attainment decreased. In multivariate logistic regression analysis, DM, CHD, ischemic cerebrovascular disease, and higher SBP were independently associated with failure to achieve LDL-C and non-HDL-C goal attainment. The type of lipid-lowering agent was not significantly correlated with LDL-C not at goal attainment but was correlated with non-HDL-C not at goal attainment. CONCLUSION: Goal attainment for both LDL-C and non-HDL-C occurs less frequently in MetS patients than in those without MetS. The residual risk due to elevated non-HDL-C levels should be considered in MetS patients. Strategies for controlling multiple risk factors in order to decrease the residual risk related to dyslipidemia in MetS patients should be recommended in future guidelines.
OBJECTIVE: To objectively evaluate lipid-lowering therapy and low-density lipoprotein cholesterol (LDL-C) and non-high-density lipoprotein cholesterol (non-HDL-C) goal attainment in metabolic syndrome (MetS) patients in China. METHODS: Data regarding patient demographics, lipid-lowering agents, lipid parameters, and cardiovascular risk profiles were analyzed for 25,317 patients of the Dyslipidemia International Study-China. MetS was defined according to criteria of the NCEP-ATP III and the 2007 Chinese Guidelines on Prevention and Treatment of Dyslipidemia in Adults. RESULTS: The prevalence of MetS was 39.9% and 37.4% according to the NCEP-ATP III and 2007 Chinese Guidelines, respectively. LDL-C goal attainment occurred less frequently among MetS patients than in those without MetS (NCEP-ATP III: 46.9% vs 68.6%; 2007 Chinese Guidelines: 52.2% vs 67.1%; p < 0.001). Similar results were obtained for non-HDL-C goal attainment (2007 Chinese Guidelines: 51.0% vs 72.0%; p < 0.001). As the risk class increased, LDL-C and non-HDL-C goal attainment decreased. In multivariate logistic regression analysis, DM, CHD, ischemic cerebrovascular disease, and higher SBP were independently associated with failure to achieve LDL-C and non-HDL-C goal attainment. The type of lipid-lowering agent was not significantly correlated with LDL-C not at goal attainment but was correlated with non-HDL-C not at goal attainment. CONCLUSION: Goal attainment for both LDL-C and non-HDL-C occurs less frequently in MetS patients than in those without MetS. The residual risk due to elevated non-HDL-C levels should be considered in MetS patients. Strategies for controlling multiple risk factors in order to decrease the residual risk related to dyslipidemia in MetS patients should be recommended in future guidelines.
Authors: Han Yang; Nan Li; Youlian Zhou; Zhilan Xiao; Haoming Tian; Ming Hu; Sheyu Li Journal: Drug Des Devel Ther Date: 2020-01-14 Impact factor: 4.162
Authors: Ibrahim Al-Zakwani; Wael Al Mahmeed; Abdullah Shehab; Mohamed Arafah; Ali T Al-Hinai; Omer Al Tamimi; Mahmoud Al Awadhi; Shorook Al Herz; Faisal Al Anazi; Khalid Al Nemer; Othman Metwally; Akram Alkhadra; Mohammed Fakhry; Hossam Elghetany; Abdel Razak Medani; Afzal Hussein Yusufali; Obaid Al Jassim; Omar Al Hallaq; Fahad Omar Ahmed S Baslaib; Haitham Amin; Khalid Al-Waili; Khamis Al-Hashmi; Raul D Santos; Khalid Al-Rasadi Journal: Diabetol Metab Syndr Date: 2016-07-26 Impact factor: 3.320